Abbott and Boston Scientific dominate the $4.6 billion drug-eluting stent market

August 9, 2011 by MassDevice staff

Abbott Labs and Boston Scientific together make up about 64 percent of U.S. drug eluting stent market.

Updated: 8/10/11 9:30 a.m.

Boston Scientific

 Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) came out as the big players in the U.S. drug-eluting stent market, together staking claim to more than half of all DES revenues.

In 2010, Boston Scientific reported $1.5 billion in DES sales and held a 33 percent market share in the U.S., lead by its Taxus and Promus stents.

The Taxus stent competes with Medtronic Inc.'s (NYSE:MDT) Endeavor DES, and Medtronic recently announced data touting their next-gen Resolute DES, not yet available in the U.S. market, as better than Taxus for avoiding in-stent late lumen loss. *

BSX could gain even more market share if predictions pan out. Analysts in June foresaw much of the stent business left behind by Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. moving over to Boston Scientific.

Abbott came in at $1.4 billion in sales, with a 31 percent corner on the market driven by its Xience DES, according to market research firm's report.